Skip to main content
Home
  • Clinical Outcome Assessments
    Clinical Outcome Assessments

    What are Clinical Outcome Assessments (COAs)? What do they measure?

    Learn more about COAs
    hero_1.jpeg
    The most trusted distributor of COAs

    700+ exclusive COA distributions on behalf of their copyright owners

    hero_2.jpeg
    PROQOLID™: the largest COA database

    7,000+ COAs described in details and accessible in this unique database

  • Services
    Services

    Mapi Research Trust provides turnkey solutions for your Clinical Outcome Assessments (COAs) strategies - including COA databases, targeted literature reviews, licensing.

    Read More
    COA Databases Patient-Centered Endpoint Intelligence COA Licensing Translation and Linguistic Validation eCOA Licensing COA Repository
    hero_3.jpeg
    About ePROVIDE™

    Online access to all our services and COA databases

    hero_2_2.jpeg
    What are eBooklets?

    Find out more about this step-by-step guidance for valid digitization of COAs

  • Author Collaboration
    Author Collaboration

    Our team is dedicated to assisting authors in the daily management of their questionnaires and all derivatives, including translations and electronic versions

    Read More
    COA distribution COA copyright and protection Promotion of COAs and developers Testimonials
    hero_3_1.jpeg
    Catalog of COAs distributed by Mapi Research Trust

    800+ exclusive distributions of COAs, accessible in ePROVIDE

  • Resources
    Resources

    ACCESS all our resources on COAs and eCOA: webinars, publications, blogs. SUBSCRIBE to receive email updates.

    Read More
    Blog Publications Useful links Webinar recordings Whitepapers
    Whitepaper-Digitizing-COAs.jpg
    New whitepaper

    Digitizing COAs: A streamlined approach to approval

    hero_4_2.jpeg
    New whitepaper

    COAs and copyright: How to mitigate risks of infringement and misuse in clinical research and practice

  • News & Events
    News & Events

    Stay informed with our latest news and check all our upcoming events. SUBSCRIBE to get email updates.

    Read More
    hero_5_1.jpeg
    News
    Hero_5_2.jpeg
    Conferences
    Hero_5_3.jpeg
    Webinars
  • About us
    About us

    Mapi Research Trust is a non-profit organization dedicated to improving patients’ quality of life by facilitating access to Clinical Outcome Assessments(COAs).

    Read More
    hero_6_1.jpeg
    Team

    A global team of multi-disciplinary experts

    hero_6_2.jpeg
    Experience

    Collecting & Processing Patient Centered Outcomes information for more than two decades

  • Contact
  1. Home
  2. Resources
  3. Mapi Publications
  4. Gastroenterology

Gastroenterology

Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Articles

  • 2017. Pavel ME et al. – Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
  • 2017. Igarashi A et al. – Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan
  • 2017. Igarashi A et al. – Cost-utility analysis of ledipasvir/ sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan
  • 2016. Zech J et al. – Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial
  • 2016. Cassuto et al. – Adherence to and acceptance of once-daily tacrolimus after kidney and liver transplant: Results from OSIRIS, a French observational study
  • 2016. Bianic F et al. – Cost-effectiveness of everolimus plus reduced tacrolimus in de novo liver-recipients in the Italian setting
  • 2015. Cure S et al. – Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients
  • 2015. Cure S et al. – Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy
  • 2015. Chassany O et al. – The Intestinal Gas Questionnaire: Development of a new instrument for measuring gas-related symptoms and their impact on daily life
  • 2014. Gilet H et al. – Measuring patients’ satisfaction with their anti-TNF treatment in severe Crohn’s disease: Scoring and psychometric validation of the satisfaction for patients in Crohn’s disease questionnaire (SPACE-Q)
  • 2011. Marant C et al. – Assessing patients’ satisfaction with anti-TNFalpha treatment in Crohn’s disease: Qualitative steps of the development of a new questionnaire
  • 2010. Dubois D et al. – Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation

Posters & Presentations

  • 2017. Congrès de la Société Française de Pédiatrie – Pleurs et inconfort du nourrisson : Echelle ColIQ©
  • 2017. Congrès du G.F.H.G.N.P – Pleurs et inconfort du nourrisson (ColIQ©): Développement d’une échelle d’évaluation standardisée
  • 2016. Journées d’Automne de Pédiatrie et Néonatologie – Prise en charge des pleurs et inconfort digestif du nourrisson: Evaluation standardisée en consultation pour les parents
  • 2016. BSG Conference – Indicators of Suboptimal Therapy Among Crohn’s Disease Patients Treated with Tumor Necrosis Factor Antagonists: Results from a Multi-National Study
  • 2016. BSG Conference – A Multinational Study to Determine Indicators of Suboptimal Therapy Among Ulcerative Colitis Patients Treated with Tumor Necrosis Factor Antagonists
  • 2016. ASCO Annual Meeting – Association of Disease Progression, Health-Related Quality of Life, and Utility in Patients with Advanced, Nonfunctional, Well-Differentiated Gastrointestinal or Lung Neuroendocrine Tumors in the Phase 3 Radiant-4 Trial
  • 2015. ISPOR European Congress – Cost-Effectiveness of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Patients with Chronic HCV in the Netherlands
  • 2015. ISPOR European Congress – Cost-Effectiveness of Cetuximab in First-Line Treatment of Patients with Metastatic Colorectal Cancer in Belgium and the Netherlands
  • 2015. ISPOR European Congress – Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with Irinotecan Based Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer. Stratifed Medicine at Work?
  • 2015. ISOQOL Annual Conference – Health-Related Quality of Life in CLARINET, a phase III Trial of Lanreotide Autogel 120 mg in Patients with Non-Functioning Entero-Pancreatic neuroendocrine Tumour: Analytical Challenges and Statistical Solutions
  • 2015. ISPOR Annual International Meeting – Importance of the Conceptual Definition of PRO Measures: A Case Study with the Linguistic Validation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) Instrument in 17 Asiatic Languages.
  • 2014. ISPOR European Congress – A Systematic Literature Review to Identify Trials in First-line RAS Wild-Type (WT) Metastatic Colorectal Cancer (MCRC) Patients
  • 2014. ISPOR European Congress – Accept® Questionnaire: Relation between Acceptance and Compliance in Liver- and Kidney-Transplanted Patients Converted to Once-Daily Tacrolimus
  • 2014. ICPE Meeting – Real World Utilization and Management of Adverse Events in Patients Treated with Direct Acting Antivirals (DAAs) in a European Cohort of Chronic Hepatitis C (CHC) Patients
  • 2013. ISPOR European Congress – What Value Can Operational Feasibility Studies Bring to Post Marketing Observational Studies (PMOS)? Example of Feasibility Study Performed in Eastern Europe to Assess Hepatitis C Viral Disease/Patient Management in Real World Setting
  • 2013. ISPOR European Congress – Systematic Literature Review in Moderate to Severe Ulcerative Colitis
  • 2013. ISPOR European Congress – Network Meta-Analysis of Approved Biologic Interventions for the Induction of Response in Ulcerative Colitis
  • 2013. ISPOR European Congress – Network Meta-Analysis of Approved Biologic Interventions for the Maintenance of Response in Ulcerative Colitis
  • 2012. ISPOR European Congress – Characteristics of Long-Acting Somatostatin (SSA) Use in Gastro-Entero-Pancreatic Neuroendocrine (GEP-NET) Tumors in the Netherlands
  • 2012. ISPOR European Congress – Cost-Effectiveness Analysis of Immunonutrition for Upper Gastrointestinal Cancer Patients Undergoing Surgery in British Hospitals
  • 2012. ISPOR European Congress – Assessing Gas-Related Symptoms and their Associated Impact on the Daily Life of the General Population and Irritable Bowel Syndrome Patients: International Development of a Questionnaire – Qualitative Steps
  • 2012. ISPOR European Congress – Finalisation and Psychometric Validation of a New Questionnaire Measuring Patient Satisfaction with Anti-TNF Treatments in Severe Crohn’s Disease
  • 2012. ACG Annual Meeting – Randomized controlled trials of treatments for irritable bowel syndrome with constipation and chronic constipation: Evaluation of measurement and reporting of efficacy and identification of evidence gaps
  • 2012. ISPOR Annual International Meeting – The Cost- Effectiveness of Telaprevir (TVR) in Combination with Pegylated Interferon-Alfa and Ribavirin (PR) for the Treatment of Genotype 1 (G1) Chronic Hepatitis C Patients: A Post-Hoc Analysis of IL-28B Subgroup
  • 2012. ISPOR Annual International Meeting – The Cost-Effectiveness of Telaprevir (TVR) in Combination with Pegylated Interferon-Alfa and Ribavirin (PR) for the Treatment of Geneotype 1 (G1) Chronic Hepatitis C Patients.
  • 2011. ISOQOL Annual Conference – The Impact of Irritable Bowel Syndrome with Constipation (IBS-C) on Children and Adolescents: Results from Qualitative Research
  • 2011. ISOQOL Annual Conference – The Impact of Chronic Constipation (CC) on Children and Adolescents: Results from Qualitative Research
  • 2011. ISPOR Annual International Meeting – IBS-C Patient Symptom Reports: Analysis of Exploratory Open-Ended Questions
  • 2010. ISPOR European Congress – Child and Parent Reports of Symptoms of Irritable Bowel Syndrome with Constipation (IBS-C): Results of Qualitative Interviews
  • 2010. ISOQOL Annual Conference – Psychometric Validation of the Ascites Impact Measure Questionnaire to Assess Patient Symptoms that Trigger a Paracentesis
  • 2010. ISOQOL Annual Conference – The Development of the Ascites Impact Measure questionnaire to Assess Patient Symptoms that Trigger a Paracentesis
  • 2010. ISOQOL Annual Conference – Conceptual Definition of PRO Measures: A Case Study with the Quality of Life in Inflammatory Bowel Disease Questionnaire (IBDQ)
  • 2010. ISOQOL Annual Conference – Development of a Pediatric Chronic Constipation Symptom Measures: Results of Qualitative Interviews with Children and Their Parents
  • 2010. ISOQOL Annual Conference – Development of Symptom Measures Reflecting the Relative Impact of Symptoms on Health-Related Quality of Life: Application to Chronic Constipation. In SYMPOSIUM 1538: The Challenges of Symptom Assessment in Clinical Research: Illustrations in Gastrointestinal Conditions
  • 2010. ISOQOL Annual Conference – Similarities and Differences in the Expression of Symptoms Across Countries: The Translations of the PAGI-SYM 20. In SYMPOSIUM 1538: The Challenges of Symptom Assessment in Clinical Research: Illustrations in Gastrointestinal Conditions
  • 2010. ISOQOL Annual Conference – The Symptoms of Irritable Bowel Syndrome with Constipation (IBS-C): Results of Qualitative Interviews with Children and their Parents. In SYMPOSIUM 1538: The Challenges of Symptom Assessment in Clinical Research: Illustrations in Gastrointestinal Conditions.
  • 2009. ISPOR European Congress – Development of a Questionnaire to Evaluate Treatment Satisfaction of Patients with Severe Crohn’s Disease: Qualitative Steps
  • 2008. ISPOR Annual International Meeting – Linguistic Validation of the Inflammatory Bowel Disease Questionnaire (IBDQ) in 35 languages
  • 1999. ISPOR Annual International Meeting – Quality of Life in Crohn Disease: A Prospective Longitudinal Study in 231 Patients
Site Branding
    ICON plc
  • Contact
  • About Us
For Clients
  • Services
  • Resources
  • ePROVIDE™
News & Events
  • News
  • Conferences
  • Webinars
Socials
  • Linkedin

Legal Footer

  • © 2025 Mapi Research Trust
  • Disclaimer
  • Privacy
  • Site Cookies
How can we help?
  • All
Popular search terms:
  • COVID-19
  • Site & Patient Recruitment
  • Oncology
  • Medical Device
  • Real World Evidence
  • Decentralised & hybrid clinical trials
  • Digital Disruption